Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: A Massive Week Of Agency Approvals

Nov 13 2017

• By Michael Cipriano

Related Content

Heplisav Seems Headed For Approval, But With More Robust Postmarketing Study

Jul 30 2017

Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details

Aug 04 2017

Keeping Track: US FDA Approvals Of Mavyret, Idhifa, Vyxeos Headline Week Of Breakthroughs, Hematology And Hematology BTDs

Aug 05 2017

Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen

Aug 11 2017

Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock

Jul 07 2017

Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

Jul 26 2017

Dynavax's Hep B Vaccine Finally Clears US FDA With Clean Label But Larger Safety Study

Nov 13 2017

Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints

May 16 2017

New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack

Mar 02 2017

Related Companies

Dynavax Technologies Corporation

Merck & Co., Inc.

Ionis Pharmaceuticals, Inc.

GSK plc

Merck & Co., Inc.

Genentech, Inc.

Roche Holding AG

Pfizer Inc.

Seagen Inc.

UCB S.A.

Bristol Myers Squibb Company

Collegium Pharmaceutical, Inc.

Keryx Biopharmaceuticals Inc.

Alnylam Pharmaceuticals Inc.

Fortress Biotech Inc.

Additional Topics

United States Approvals Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window